UNITED ~~STATESSECURITIES~~STATES ~~AND EXCHANGE COMMISSIONWashington, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended: September 30, 2021
	For the fiscal year ended: March 31, 2022
	or
☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from ___________ to ___________

Commission file number: 333-210922

MED SPA VACATIONS INC.

(Exact name of registrant as specified in its charter)

Nevada

47-5268172

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

500 W. 5th Street, Suite 800, PMB #59, Winston Salem, NC 27101

(Address of principal executive offices)

(845) 548-3280

(Registrant ’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act: ~~None~~

Title of each class ~~Trading Symbol~~TradingSymbol(s) Name of each exchange on which registered None N/A N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ~~Yes ☒ No ☐~~

Yes

☒ No ☐

(Note: The registrant is a voluntary filer of reports under Section 13 or 15(d) of the Securities Exchange Act of 1934; the registrant has filed during the preceding 12 months all reports it would have been required to file by Section 13 or 15(d) of the Securities Exchange Act of 1934 if the registrant had been subject to one of such Sections.)

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒☐

If an emerging growth company, indicate by check mark if this registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of ~~November~~April 327, ~~2021~~2022, there were 10,005,000 shares of the registrant’s common stock, par value $0.001 per share, issued and outstanding.

MED SPA VACATIONS INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~SEPTEMBER~~MARCH 3031, ~~2021~~2022

TABLE OF CONTENTS

		PAGE
	PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	F-12
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	76
Item 4.	Controls and Procedures	76
	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	87
Item 1A.	Risk Factors	87
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	87
Item 3.	Defaults Upon Senior Securities	87
Item 4.	Mine Safety Disclosures	87
Item 5.	Other Information	87
Item 6.	Exhibits	98
	SIGNATURES	109

Table of Contents

MED SPA VACATIONS, INC.

INDEX TO AUDITED FINANCIAL STATEMENTS

FOR THE PERIOD ENDED ~~SEPTEMBER~~MARCH 3031, ~~2021~~2022

		Page

Unaudited Balance Sheets		F-2

Unaudited Statements of Operations		F-3

Unaudited Statements of Stockholders’ Deficit		F-4

Unaudited Statements of Cash Flows		F-5

Notes to the Unaudited Financial Statements		F-6

F-1 Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

MED SPA VACATIONS INC.

Balance Sheets

(Unaudited)

	September 30,			December 31,
	March 31,			December 31,
	2021			2020
	2022			2021
ASSETS
Current Assets:
Cash	$	155,~~029~~899		$	-2,266
Total Current Assets		155,~~029~~899			-2,266
Total Assets	$	155,~~029~~899		$	-2,266
LIABILITIES AND STOCKHOLDERS’ DEFICIT
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities	$	507		$	36,664
Accounts payable	$	6		$	6
Accrued interest - related party		~~856~~1,313			-1,196
Due to related party		-			44,322
Note payable - related party		168,250			128,750
Note payable - related party		115,000			-
Total Current Liabilities		169,569			129,952
Total Current Liabilities		116,363			80,986
Total Liabilities		169,569			129,952
Total Liabilities		116,363			80,986
Commitments and Contingencies (Note 6)
Stockholders’ Deficit:
Stockholders' Deficit:
Preferred stock, $0.001 par value, 25,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock, $0.001 par value, 100,000,000 shares authorized, 10,005,000 shares and 14,350,000 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively		10,005			14,350
Common stock, $0.001 par value, 100,000,000 shares authorized, 10,005,000 shares issued and outstanding		10,005			10,005
Additional paid-in capital		395,296			~~272~~395,~~445~~296
Accumulated deficit		(~~506~~568,~~635~~971	)		(~~367~~532,~~781~~987	)
Total Stockholders’ Deficit		(101,334	)		(80,986	)
Total Stockholders' Deficit		(163,670	)		(127,686	)
Total Liabilities and Stockholders’ Deficit	$	15,029		$	-
Total Liabilities and Stockholders' Deficit	$	5,899		$	2,266

The accompanying notes to the unaudited financial statements are an integral part of these statements.

F-2

Table of Contents

MED SPA VACATIONS INC.

Statements of Operations

(Unaudited)

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2021			2020			2021			2020
	2022			2021
Operating Expenses
General and administrative	$	~~770~~955		$	-570		$	~~2,211~~		$	-
Management fees - related party		3,000			-1,000			~~6,000~~			-
Professional fees		1929,~~421~~756			-75,535			~~126,037~~			-
Total Operating Expenses		2333,~~191~~711			-77,105			~~134,248~~			-
Loss from operations		(2333,~~191~~711	)		-(77,105	)		~~(134,248~~	)		-
Other Income (Expense)
Other Expense
Interest expense		-			-(1,159	)		~~(2,250~~	)		-
Interest expense - related party		(12,~~518~~273	)					~~(2,356~~	)
Net Other Expense		(12,~~518~~273	)		-(1,159	)		~~(4,606~~	)		-
Loss Before Provision for Income Taxes		(24,709	)		-			(138,854	)		-
Net Loss	$	(35,984	)	$	(78,264	)
Provision for Income Taxes		-			-			-			-
Net loss per common share: Basic and Diluted	$	(0.00	)	$	(0.01	)
Loss from Discontinued Operation, Net of Tax Benefits		-			-						-
Weighted average number of common shares outstanding: Basic and Diluted		10,005,000			11,743,000
Net Loss	$	(24,709	)	$	-		$	(138,854	)	$	-
Net loss per common share: Basic and Diluted	$	(0.00	)	$	-		$	(0.01	)	$	-
Weighted average number of common shares outstanding: Basic and Diluted		10,005,000			14,350,000			10,577,967			14,350,000

The accompanying notes to the unaudited financial statements are an integral part of these statements.

F-3

Table of Contents

MED SPA VACATIONS INC.

Statements of Stockholders’ Deficit

(Unaudited)

For the ~~Nine~~Three Months Ended ~~September~~March 3031, ~~2021~~2022

							Additional					Total
	Common stock						Paid-in		Accumulated			Shareholders’'
	Shares			Amount			Capital		Deficit			Deficit
Balance - December 31 2020		14,350,000		$	14,350		$	272,445	$	(367,781	)	$	(80,986	)
Balance - December 30, 2021		10,005,000		$	10,005		$	395,296	$	(532,987	)	$	(127,686	)
Cancellation of common stock		(4,345,000	)		(4,345	)		4,345		-			-
Net loss		-			-			-		(35,984	)		(35,984	)
Debt forgiveness by related party		-			-			118,506		-			118,506
Balance - March 31, 2022		10,005,000		$	10,005		$	395,296	$	(568,971	)	$	(163,670	)
Net loss		-			-			-		(78,264	)		(78,264	)
Balance - March 31 2021		10,005,000			10,005			395,296		(446,045	)		(40,744	)
Net loss		-			-			-		(35,881	)		(35,881	)
Balance - June 30 2021		10,005,000		$	10,005		$	395,296	$	(481,926	)	$	(76,625	)
Net loss		-			-			-		(24,709	)		(24,709	)
Balance - September 30 2021		10,005,000		$	10,005		$	395,296	$	(506,635	)	$	(101,334	)

For the ~~Nine~~Three Months Ended ~~September~~March 3031, ~~2020~~2021

							Additional					~~Total~~
	Common stock						Paid-in		Accumulated			~~Shareholders’~~
	Shares			Amount			Capital		Deficit			~~Deficit~~Total
Balance - December 31 2019		14,350,000		$	14,350		$	272,445	$	(321,123	)	$	(34,328	)
Balance - December 31 2020		14,350,000		$	14,350		$	272,445	$	(367,781	)	$	(80,986	)
Net loss		-			-			-		-			-
Cancellation of common stock		(4,345,000	)		(4,345	)		4,345		-			-
Balance - March 31 2020		14,350,000			14,350			272,445		(321,123	)		(34,328	)
Debt forgiveness by related party		-			-			118,506		-			118,506
Net loss		-			-			-		-(78,264	)		-(78,264	)
Balance - June 30 2020		14,350,000		$	14,350		$	272,445	$	(321,123	)	$	(34,328	)
Balance - March 31 2021		10,005,000		$	10,005		$	395,296	$	(446,045	)	$	(40,744	)
Net loss		-			-			-		-			-
Balance - September 30 2020		14,350,000		$	14,350		$	272,445	$	(321,123	)	$	(34,328	)

The accompanying notes to the unaudited financial statements are an integral part of these statements.

F-4

Table of Contents

MED SPA VACATIONS INC.

Statements of Cash Flow

(Unaudited)

	Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2021			2020
	2022			2021
Cash Flows from Operating Activities
Net loss	$	(~~138~~35,~~854~~984	)	$	-(78,264	)
Changes in operating assets and liabilities:
Expenses paid by related party		~~74,184~~-			~~875~~74,184
Accounts payable and accrued liabilities		~~(36,157~~-	)		(931,~~717~~901	)
Accrued interest - related party		856			-
Accrued note payable interest		-			1,159
Net cash used in operating activities		(99,971	)		(8,842	)
Accrued note payable interest - related party		117			-
Net cash used in operating activities		(35,867	)		(34,822	)
Cash Flows from Financing Activities
Proceed of promissory note payable		~~150,000~~-			-150,000
Repayment of promissory note payable		(150,000	)		-
Repayment of promissory note payable -related party		(15,000	)		-
Proceed of promissory note payable - related party		~~115~~54,~~000~~500			-
Net cash provided by Financing Activities		~~115~~39,~~000~~500			-150,000
Net change in cash for period		153,~~029~~633			(8115,~~842~~178	)
Cash at beginning of period		-2,266			~~8,842~~-
Cash at end of period	$	155,~~029~~899		$	-115,178
Supplemental Cash Flow Information
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	32,~~750~~156		$	-
Non Cash Investing and Financing Activities
Related party debt forgiven recorded as additional paid in capital	$	~~118,506~~-		$	-118,506
Cancellation of common stock	$	~~4,345~~-		$	-4,345

The accompanying notes to the unaudited financial statements are an integral part of these statements.

F-5

Table of Contents

MED SPA VACATIONS INC.

Notes to the Unaudited Financial Statements

~~September~~March 3031, ~~2021~~2022

Note 1 - ~~Organization,~~Summary ~~Description~~ of ~~Business~~Significant Accounting Policies

~~Med~~Basis ~~Spa~~of ~~Vacations,~~Presentation ~~Inc, (the “Company”), was incorporated in the State~~ of ~~Nevada~~Unaudited onInterim ~~October~~Financial ~~5, 2015. The Company’s office address is 500 W. 5th Street, Suite 800, PMB #59, Winston Salem, NC 27101.~~ Statements

The ~~Company’s~~accompanying ~~original~~unaudited ~~plan~~interim ~~was~~financial tostatements ~~develop~~have abeen ~~business~~prepared ~~that~~in ~~specialized~~accordance with accounting principles generally accepted in ~~marketing~~the ~~health~~United ~~and~~States ~~wellness~~of ~~vacations~~America tofor ~~both~~interim ~~individuals~~financial statements and ~~corporate~~with ~~groups~~the ~~looking~~instructions to ~~revitalize~~Form 10-Q and ~~develop~~Article a8 ~~fuller~~of ~~day~~Regulation S-~~to-day~~X ~~life~~of the United States Securities and Exchange Commission (“SEC”). ~~The~~Accordingly, ~~Company~~they ~~was~~do not ~~successful~~contain inall ~~its~~information ~~efforts~~ and ~~discontinued~~footnotes ~~that~~required ~~line~~by accounting principles generally accepted in the United States of ~~business~~America for annual financial statements. ~~Since~~In ~~that~~the ~~time~~opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company ~~has~~as ~~been~~of aMarch ~~shell~~31, ~~company~~2022, asand ~~that~~the ~~term~~results isof ~~defined~~operations inand ~~Rule~~cash ~~12b-2~~flows for the periods presented. The results of operations for the ~~Exchange~~period ~~Act~~ended March 31, 2022, are not necessarily indicative of ~~1934~~the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, as2021, ~~amended~~filed (with the ~~“Exchange~~SEC ~~Act”)~~on March 24, 2022.

~~Going~~Use ~~forward,~~of ~~the~~Estimates ~~Company intends to seek, investigate~~ and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s shareholders. No specific assets or businesses have been definitively identified and there is no certainty that any such assets or business will be identified or that any transactions will be consummated.Assumptions

~~Change~~The preparation of ~~Control~~financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

OnCash ~~February 4, 2021, Kynson Health Limited, a BVI entity (Kynson”), which was our majority stockholder, closed stock purchase~~ and ~~sale~~Cash transactions pursuant to which Kynson sold an aggregate of 9,985,329 restricted shares of the Company’s Common Stock to eleven purchasers at a purchase price of $0.030044 per share, or an aggregate purchase price of $299,998.60 (the “Kynson Share Sale Transaction”). Upon the closing of the Kynson Share Sale Transaction, OuYang XingYing, who controlled Kynson, and was our President, Secretary and Treasurer and sole member of the Company’s board of the directors, resigned from all positions she held with the Company and, in connection with her resignation, she relinquished her roles as the Company’s “Principal Executive Officer” and “Principal Financial and Accounting Officer.” Effective immediately upon Ms. Yang’s resignation, John D. Rollo was appointed as the Company’s President, Secretary and Treasurer, and as the sole member of the Company’s board of the directors. In connection with his appointments, Mr. Rollo was designated as the “Principal Executive Officer” and “Principal Financial and Accounting Officer” of the Company for SEC reporting purposes. In connection with and as a condition to, the consummation of the Kynson Share Sale Transaction, eleven shareholders of the Company returned an aggregate of 4,345,000 shares of the Company’s Common Stock to the Company for cancellation, in consideration for $0.001 per share. As a result of the Kynson Share Sale Transaction and simultaneous cancellation of 4,345,000 shares by eleven stockholders, there was a change in control of the Company.Equivalents

OnThe ~~May~~Company ~~21,~~considers ~~2021,~~all ~~John~~highly D.liquid ~~Rollo,~~instruments ~~the~~with ~~President,~~a ~~Treasurer~~maturity ~~and~~of ~~Secretary~~three ~~and~~months ~~the~~or ~~sole~~less ~~member~~at of the ~~Company’s~~time ~~board~~ of ~~directors~~issuance ~~(the~~to ~~“Board”),~~be ~~resigned~~cash ~~from all positions he held with the Company~~equivalents. ~~Effective~~The ~~immediately upon Mr. Rollo’s resignation, Irwin Schneidmill was appointed as the~~ Company’s ~~President,~~had ~~Secretary~~ $5,899 and ~~Treasurer~~$2,266 in ~~and~~cash as ~~the sole member~~ of ~~the~~March ~~Company’s board of the directors. In connection with his appointments~~31, ~~Mr.~~2022 ~~Schneidmill was designated as the “Principal Executive Officer”~~ and ~~“Principal~~December ~~Financial~~31, ~~and~~2021, ~~Accounting Officer” of the Company for SEC reporting purposes~~respectively.

~~Note 2 - Summary of Significant Accounting Policies~~Reclassification

~~Basis~~Certain ofaccounts ~~Presentation~~from ofprior ~~Unaudited~~periods ~~Interim~~have ~~Financial~~been ~~Statements~~reclassified to conform to the current period presentation.

~~The~~Note ~~accompanying~~2 ~~unaudited~~– ~~interim~~Going financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of September 30, 2021, and the results of operations and cash flows for the periods presented. The results of operations for the period ended September 30, 2021, are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 30, 2021.Concern

~~F-6~~Going ~~Table~~concern ofand ~~Contents~~Liquidity Considerations

~~Use~~The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of ~~Estimates~~assets and ~~Assumptions~~the liquidation of liabilities in the normal course of business. As of March 31, 2022, the Company has reoccurring losses from operations, an accumulated deficit of $568,971 and has earned no revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2022.

The ~~preparation~~ability of ~~financial~~the ~~statements~~Company ~~in conformity with GAAP requires management~~ to ~~make~~emerge ~~estimates~~from ~~and~~the ~~assumptions~~early ~~that~~stage ~~affect~~is ~~the~~dependent ~~reported~~upon, ~~amounts~~among ofother ~~assets~~things, ~~and~~obtaining ~~liabilities~~additional ~~and~~financing ~~disclosure~~to ofcontinue ~~contingent~~operations, ~~assets~~ and ~~liabilities~~development ~~at the date~~ of ~~the~~its ~~financial~~business ~~statements~~plan. ~~and~~In ~~the~~response ~~reported~~to ~~amounts~~these ofproblems, ~~revenues~~management ~~and~~intends ~~expenses~~to ~~during~~raise ~~the~~additional ~~reporting~~funds ~~period.~~through ~~Actual~~public ~~results~~or ~~could~~private ~~differ~~placement ~~from those estimates~~offerings.

~~Cash~~These ~~and~~factors, ~~Cash~~among ~~Equivalents~~others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~The~~F-6 ~~Company~~Table ~~considers all highly liquid instruments with a maturity~~ of ~~three months or less at the time of issuance to be cash equivalents. The Company had $15,029 and $0 in cash as of September 30, 2021 and December 31, 2020, respectively.~~Contents

Note 23 – ~~Going~~Related ~~Concern~~Party Transactions

Going concern and Liquidity Considerations

	(i)	During the three months ended March 31, 2022 and 2021, the Company’s controlling shareholder advanced to the Company an amount of $0 and $74,184, respectively, to pay certain expenses on behalf of the Company.

	(ii)	During the three months ended March 31, 2022 and 2021, the Company paid $3,000 and $1,000 of management fees to the Director of the Company.

~~The~~Note ~~accompanying~~payable ~~financial~~– ~~statements~~related have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of September 30, 2021, the Company has reoccurring losses from operations, an accumulated deficit of $506,635 and has earned no revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2021.party

~~The~~On ~~ability~~May 10, 2021, the Company received a loan of $100,000 from Peter L. Coker, Sr., a shareholder of the Company. To evidence said loan, the Company issued to ~~emerge~~Mr. ~~from~~Coker a promissory note in the ~~early~~principal ~~stage~~amount isof ~~dependent~~$100,000 (in ~~upon~~this case, ~~among~~the ~~other~~“Note”), ~~things~~with a maturity date of May 9, ~~obtaining~~2022. ~~additional~~Interest ~~financing~~on tothe ~~continue~~Note ~~operations~~accrues on the principal amount at the rate of six percent (6%) per annum, and ~~development~~shall be paid on a quarterly basis, in the amount of ~~its~~$1,500 ~~business~~per ~~plan.~~quarter, Inon ~~response~~the tofollowing ~~these~~dates: ~~problems~~August 10, ~~management~~2021, ~~intends~~November to10, ~~raise~~2021, ~~additional~~February ~~funds~~10, ~~through~~2022, ~~public~~and orMay ~~private~~10, ~~placement~~2022. ~~offerings~~The Company may prepay any amounts due under the Note without penalty or premium.

~~These~~On ~~factors~~September 28, ~~among~~2021, ~~others~~the Company received a loan of $15,000 from ~~raise~~Peter ~~substantial~~L. ~~doubt~~Coker, ~~about~~Sr., a shareholder of the Company’s. ~~ability~~To evidence said loan, the Company issued to ~~continue~~Mr. asCoker a ~~going~~promissory ~~concern~~note in the principal amount of $15,000 (in this case, the “Note”), with a maturity date of September 27, 2022. Interest on the Note accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $225 per quarter, on the following dates: December 28, 2021, March 28, 2022, June 28, 2022, and September 27, 2022. The ~~accompanying~~Company ~~financial~~may ~~statements~~prepay doany amounts due under the Note without penalty or premium. On March 29, 2022, the Company repaid in full all outstanding principal note of $15,000 and an interest of $225. The Company did not ~~include~~incur any ~~adjustments~~early ~~that~~termination ~~might~~penalties as a result ~~from~~of the ~~outcome~~repayment of ~~this~~indebtedness ~~uncertainty~~and termination of the loan.

On October 27, 2021, the Company received a loan of $5,250 from Peter L. Coker, Sr., a shareholder of the Company. To evidence said loan, the Company issued to Mr. Coker a promissory note in the principal amount of $5,250 (in this case, the “Note”), 3with –a maturity date of October 26, 2022. Interest on the Note ~~Payable~~accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $78.75 per quarter, on the following dates: January 27, 2022, April 27, 2022, July 27, 2022, and October 26, 2022. The Company may prepay any amounts due under the Note without penalty or premium.

On November 29, 2021, the Company received a loan of $8,500 from Fiesta Homes, LLC (“Fiesta”), which controlled by family member of a shareholder of the Company. To evidence said loan, the Company issued to Fiesta a promissory note in the principal amount of $8,500 (in this case, the “Note”), ~~payable~~with a maturity date of November 29, 2022. Interest on the Note accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $127.50 per quarter, on the following dates: February 28, 2022, May 31, 2022, August 29, 2022, and November 29, 2022. The Company may prepay any amounts due under the Note without penalty or premium.

On ~~February~~January 1218, ~~2021~~2022, the Company received a loan ~~in the amount~~ of $~~150~~15,000 from ~~(the~~12804 Morehead Investments, LLC (“~~Loan~~Morehead”), ~~from~~which ~~Hometown~~controlled ~~International~~by ~~Inc.,~~ a ~~Nevada~~shareholder ~~corporation~~of ~~(“Hometown”)~~the Company. To evidence ~~the~~said ~~Loan~~loan, the Company issued to Morehead a promissory note in the principal amount of $~~150~~15,000 (in this case, the “Note”) ~~to Hometown~~, with a maturity date of January ~~February 11~~18, ~~2022~~2023. Interest ~~accrues~~ on the ~~principal~~Note ~~amount~~accrues ofon the ~~Note~~principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $~~2,250~~225 per quarter, on the following dates: ~~May~~April 1218, ~~2021~~2022, ~~August~~July 1218, ~~2021~~2022, ~~November~~October 1218, ~~2021~~2022, and ~~February~~January 1118, ~~2022~~2023. The Company may prepay any amounts due under the Note without penalty or premium. On May 12, 2021, the Company repaid in full all outstanding principal note of $150,000 and an interest of $2,250. The Company did not incur any early termination penalties as a result of the repayment of indebtedness and termination of the loan.

On March 1, 2022, the Company received a loan of $19,500 from Morehead, which controlled by a shareholder of the Company. To evidence said loan, the Company issued to Morehead a promissory note in the principal amount of $19,500 (in this case, the “Note”), ~~payable~~with –a ~~related~~maturity ~~party~~date of March 1, 2023. Interest on the Note accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $292.50 per quarter, on the following dates: June 1, 2022, September 1, 2022, December 1, 2022, and March 1, 2023. The Company may prepay any amounts due under the Note without penalty or premium

OnF-7 ~~May~~Table ~~10, 2021, the Company received a loan~~ of $100,000 from Peter L. Coker, Sr., a shareholder of the Company. To evidence said loan, the Company issued to Mr. Coker a promissory note in the principal amount of $100,000 (the “Note”), with a maturity date of May 9, 2022. Interest on the Note accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $1,500 per quarter, on the following dates: August 10, 2021, November 10, 2021, February 10, 2022, and May 10, 2022. The Company may prepay any amounts due under the Note without penalty or premium. Contents

~~F-7~~On ~~Table~~March 1, 2022, The Company received a loan of ~~Contents~~$20,000 from Peter L. Coker, Sr., a shareholder of the Company. To evidence said loan, the Company issued to Mr. Coker a promissory note in the principal amount of $20,000 (in this case, the “Note”), with a maturity date of March 1, 2023. Interest on the Note accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $300 per quarter, on the following dates: June 1,2022, September 1, 2022, December 1, 2022, and March 1, 2023. The Company may prepay any amounts due under the Note without penalty or premium

OnDuring ~~September 28, 2021,~~ the ~~Company~~three ~~received~~months aended ~~loan~~March ~~of $15~~31,~~000~~ ~~from Peter L. Coker~~2022, ~~Sr., a shareholder of~~ the Company. Torecorded ~~evidence~~interest ~~said~~expense ~~loan, the Company issued to Mr. Coker a promissory note in the principal amount~~ of $152,~~000~~273 and ~~(the~~repaid ~~“Note”)~~$2,156 of ~~with~~interest. aAs ~~maturity date~~ of ~~September~~March 2731, 2022., ~~Interest on~~ the ~~Note~~outstanding ~~accrues~~balances ~~on the principal amount at the rate~~ of ~~six~~promissory ~~percent~~note ~~(6%)~~– ~~per~~related ~~annum,~~party and ~~shall~~accrued beinterest ~~paid~~were ~~on a quarterly basis~~$168,250 and ~~in the amount of~~ $~~225 per quarter~~1, ~~on the following dates: December 28~~313, ~~2021, March 28, 2022, June 28, 2022, and September 27, 2022~~respectively. ~~The Company may prepay any amounts due under the Note without penalty or premium.~~

~~During~~Note ~~the~~4 ~~nine months ended September 30, 2021, the Company recorded interest expense of $2,356 and repaid $1,500 interest. As of September 30, 2021, the outstanding balance of promissory note~~ – ~~related party and accrued interest were $115,000 and $856, respectively~~Commitments.

~~Note~~On 4June –18, ~~Related~~2018, ~~Party~~the ~~Transactions~~Company entered into a consulting agreement (the “Benchmark Consulting Agreement”) with Benchmark Capital, LLC, a New Jersey limited liability company (“Benchmark”), effective as of July 1, 2021, pursuant to which Benchmark will assist the Company in connection with all fillings required by the Company to be made with the SEC, for a consulting fee of $2,500 per month. The Benchmark Consulting Agreement can be terminated by either party, at any time, upon 30 days’ prior written notice. During the three months ended March 31, 2022, the Company incurred and paid consulting fees of $7,500.

	(i)	During the nine months ended September 30, 2021, and 2020, the Company’s controlling shareholder advanced to the Company an amount of $78,184 and $875, respectively, to pay certain expenses on behalf of the Company.
		On February 4, 2021, the former majority shareholder of the Company, which was controlled by the Company’s former sole officer and director, canceled and released the Company from $118,506 it was owed.
	(ii)	During the nine months ended September 30, 2021, the Company paid $2,000 management fees to the former Director of the Company who resigned on May 21, 2021 and paid $4,000 management fees to the Director of the Company who was appointed on May 21, 2021.

Note 5 – Subsequent Events

~~Note~~Management 5has -evaluated ~~Stockholders’~~subsequent ~~Equity~~events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

OnF-8 ~~February~~Table ~~4, 2021, eleven shareholders~~ of the Company returned an aggregate of 4,345,000 shares (the “Cancelled Shares”) of the Company’s Common Stock to the Company for cancellation. The Cancelled Shares were returned to the Company’s number of authorized and unissued shares of Common Stock.Contents

As of September 30, 2021, and December 31, 2020, the Company had 10,005,000 and 14,350,000 shares of Common Stock issued and outstanding, respectively.

Note 6 – Commitments

On February 5, 2021, the Company entered into a one-year consulting agreement (the “Tryon Consulting Agreement”) with Tryon Capital LLC, a North Carolina limited liability company (“Tryon”), pursuant to which Tryon will provide the Company with financial and strategic consulting services in consideration for a consulting fee of $2,500 per month. The Tryon Consulting Agreement was terminated on June 18, 2021 with effective date of June 30, 2021. The Company and Tryon also agreed to release each other from any claims relating to the Tryon Consulting Agreement. During the nine months ended September 30, 2021, the Company incurred consulting fees of $12,500.

On February 12, 2021, the Company entered into a one-year consulting agreement (the “Benzions Consulting Agreement”) with Benzions LLC, a Delaware limited liability company (“Benzions”), effective as of March 1, 2021, pursuant to which Benzions will provide certain strategic advisory and investor relations services to the Company in consideration for a consulting fee of $4,000 per month. The Benzions Consulting Agreement was terminated on May 19, 2021 with effective date of immediately. The Company and Benzions also agreed that all responsibilities of the other party under the Benzions Consulting Agreement have been fully performed. During the nine months ended September 30, 2021, the Company incurred consulting fees of $12,000.

On June 18, 2018, the Company entered into a consulting agreement (the “Benchmark Consulting Agreement”) with Benchmark Capital, LLC, a New Jersey limited liability company (“Benchmark”), effective as of July 1, 2021, pursuant to which Benchmark will assist the Company in connection with all filling required by the Company to be made with the SEC, for a consulting fee of $2,500 per month. The Benchmark Consulting Agreement can be terminated by either party, at any time, upon 30 days’ written notice. During the nine months ended September 30, 2021, the Company incurred consulting fees of $7,500 and the amount due to the consultant was $500 as of September 30, 2021.

Note 7 – Subsequent Events

On October 27, 2021, the Company received a loan of $5,250 from Peter L. Coker, Sr., a shareholder of the Company. To evidence said loan, the Company issued to Mr. Coker a promissory note in the principal amount of $5,250, with a maturity date of October 26, 2022. Interest on the note accrues on the principal amount at the rate of six percent (6%) per annum, and shall be paid on a quarterly basis, in the amount of $78.75 per quarter, on the following dates: January 27, 2022, April 27, 2022, July 27, 2022 and October 26, 2022.

F-8 Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses. Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes” and similar language. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed herein. You should carefully review the risks described herein and in other documents we file from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances after the date of this document.

Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.

All references in this Form 10-Q to the “Company,” “we,” “us,” or “our,” are to Med Spa Vacations Inc.

General Overview

We were incorporated in the State of Nevada on October 5, 2015 to develop a business that ~~specializes~~specialized in marketing health and wellness vacations to both individuals and corporate groups looking to revitalize and develop a fuller day-to-day life. Because we were not able to raise sufficient capital to execute our original business plan, we discontinued that line of business. Our office address is 500 W. 5th Street, Suite 800, PMB #59, Winston Salem, NC 27101.

Because we were not able to raise sufficient capital to execute our original business plan, we discontinued that line of business.

The Company is a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended. The Company is seeking a business combination with a private entity whose business would present an opportunity for its shareholders. No specific assets or businesses have been definitively identified and there is no certainty that any such assets or business will be identified or that any transactions will be consummated.

On February 4, 2021, our controlling stockholder Kynson Health Limited, a company incorporated and existing under the law of the British Virgin Islands (“Kynson Health”), closed stock purchase and sale transactions pursuant to which Kynson Health sold an aggregate of 9,985,329 restricted shares (the “Shares”) of the Company’s common stock, $0.001 par value per share, to eleven purchasers at a purchase price of $0.030044 per share, or an aggregate purchase price of $299,998.60 (the “Share Sale Transaction”). The ~~shares~~Shares represented approximately 99.8% of the Company’s issued and outstanding shares of common stock as of the date of the closing of the Share Sale Transaction, taking into account the share cancellations further described below.

On February 4, 2021, in connection with, and as a condition to, the consummation of the Share Sale Transaction, eleven shareholders of the Company returned an aggregate of 4,345,000 shares of the Company’s common stock to the Company for cancellation, in consideration for $0.001 per share. Said shares were returned to the Company’s number of authorized and unissued shares of common stock.

We have no revenues and limited cash on hand. We have sustained losses since inception. We have never declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

Table of Contents

Results of Operations

Three Months Ended ~~September~~March 3031, ~~2021~~2022, Compared to Three Months Ended ~~September~~March 3031, ~~2020~~2021

Our results of operations for the three months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021 are summarized below:

	Three Months Ended
	September 30,
	March 31,
	2021			2020			Change
	2022			2021			Change
Revenue	$	-		$	-		$	-
Operating expenses		2333,~~191~~711			-77,105			23(43,~~191~~394	)
Other expenses		12,~~518~~273			-1,159			1,~~518~~114
Net loss	$	(2435,~~709~~984	)	$	-(78,264	)	$	~~(24~~42,~~709~~280	)

Revenue

During the three months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021, we did not generate any revenues from operations.

Operating Expenses

Operating expenses ~~consisted~~for ofthe ~~professional~~three ~~fees~~months ofended ~~$19~~March 31,~~421~~ 2022, ~~management~~and ~~fees~~2021 ofwere $333,~~000~~711 and ~~general and administrative expenses of~~ $~~770~~77,105, ~~during~~respectively. For the three months ended ~~September~~March 3031, ~~2021~~2022, ~~compared to~~ operating expenses consisted of $0professional ~~during~~fees ~~the~~of ~~three~~$29,756, ~~months~~management ~~ended~~fees ~~September~~of 30$3,000 ~~2020.~~and Wegeneral ~~did~~and ~~not~~administrative ~~incur any~~ expenses ~~during~~of $955. For the three months ended ~~September~~March 3031,2021, ~~2020~~operating expenses consisted of professional fees of $75,535, asmanagement ~~the~~fees ~~Company~~of ~~was~~$1,000 ~~delinquent~~and ~~with~~general ~~its~~and ~~SEC~~administrative ~~filings~~expenses of $570.

The decrease in operation expenses is primarily the result of a reduction in legal and consulting fees of $46,000 as compared to the corresponding period in the prior year.

Other Expenses

~~Other~~For ~~expenses~~the ~~consisted~~three ofmonths $1ended March 31,~~518~~ in2022 and 2021, other expenses consisted of interest on promissory notes of $2,273 and $1,159, respectively.

Net Loss

As a result of the foregoing, we incurred a net loss of $2435,~~709~~984 for the three months ended ~~September~~March 3031, ~~2021~~2022, compared to a net loss of $078,264 for the three months ended ~~September~~March 3031, ~~2020~~2021.

Nine Months Ended September 30, 2021, Compared to Nine Months Ended September 30, 2020

Our results of operations for the nine months ended September 30, 2021 and 2020 are summarized below:

	Nine Months Ended
	September 30,
	2021			2020		Change
Revenue	$	-		$	-	$	-
Operating expenses		134,248			-		134,248
Other expenses		4,606			-		4,606
Net loss	$	(138,854	)	$	-	$	(138,854	)

Revenues

During the nine months ended September 30, 2021 and 2020, we did not generate any revenues from operations.

Operating Expenses

Operating expenses consisted of professional fees of $126,037, management fees of $6,000 and general and administrative expenses of $2,211 during the nine months ended September 30, 2021, compared to operating expenses of $0 during the nine months ended September 30, 2020. We did not incur any expenses during the nine months ended September 30, 2020 as the Company was delinquent with its SEC filings.

4 Table of Contents

Other Expenses

Other expenses consisted of $4,606 in interest on promissory notes.

Net Loss

As a result of the foregoing, we incurred a net loss of $138,854 for the nine months ended September 30, 2021, compared to a net loss of $0 for the nine months ended September 30, 2020.

Liquidity and Capital Resources

	September 30,			December 31,
	March 31,			December 31,
	2021			2020			Change
	2022			2021			Change
Cash	$	155,~~029~~899		$	-2,266		$	153,~~029~~633
Total Assets	$	155,~~029~~899		$	-2,266		$	153,~~029~~633
Total Liabilities	$	~~116~~169,~~363~~569		$	80129,~~986~~952		$	3539,~~377~~617
Stockholders’ Deficit	$	(101,334	)	$	(80,986	)	$	(20,348	)
Stockholders' Deficit	$	(163,670	)	$	(127,686	)	$	(35,984	)
Working Capital Deficit	$	(~~101~~163,~~334~~670	)	$	(80127,~~986~~686	)	$	(2035,~~348~~984	)

As of the date of this report, we had yet to generate any revenues from our business operations.

As4 ofTable ~~September 30, 2021, we had current assets~~ of $15,029, current liabilities of $116,363, and our working capital deficit was $101,334. The increase in working capital deficit during the nine months ended September 30, 2021 was mainly due to an increase in notes payable related to promissory notes issued to a related party of $115,000 and offset by a decrease in due to related party of $44,322 and accounts payable and accrued liabilities of $36,157. We anticipate that our current liquidity is not sufficient to meet the obligations associated with being a company that is fully reporting with the SEC.Contents

As of March 31, 2022, we had current assets of $5,899, current liabilities of $169,569, and our working capital deficit was $163,670. The increase in working capital deficit during the three months ended March 31, 2022, compared to three months ended March 31,2021, was mainly due to an increase in notes payable related to promissory notes issued to a related party of $39,500 and offset by an increase in cash of $3,633. We anticipate that our current liquidity is not sufficient to meet the obligations associated with being a company that is fully reporting with the SEC.

To date, we have managed to keep our monthly cash flow requirement low for two reasons. First, our sole officer draws only a nominal salary at this time. Second, we have been able to keep our operating expenses to a minimum by operating in space provided at no or nominal expense by our shareholders or consultants.

We currently have no external sources of liquidity such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplates our continuation as a going concern. We have not yet generated any revenue and have incurred losses to date of $~~506~~568,~~635~~971. In addition, our current liabilities exceed our current assets by $~~101~~163,~~334~~670. These factors raise substantial doubt about our ability to continue operating as a going concern. Our ability to continue our operations as a going concern, realize the carrying value of our assets, and discharge our liabilities in the normal course of business is dependent upon our ability to raise capital sufficient to fund our commitments and ongoing losses, and ultimately generate profitable operations.

5 Table of Contents

Cash Flows

	Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2021			2020
	2022			2021
Cash used in operating activities	$	(9935,~~971~~867	)	$	(834,~~842~~822	)
Cash provided by Investing Activities	$	-		$	-
Cash provided by financing activities	$	~~115~~39,~~000~~500		$	-150,000
Net Change In Cash	$	153,~~029~~633		$	(8115,~~842~~178	)

Operating Activities

For the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, net cash used in operating activities was $9935,~~971~~867, related to our net loss of $~~138~~35,~~854~~984, ~~increased by a decrease in accounts payable and accrued liabilities of $36,157 and~~ reduced by an increase in ~~expenses paid by related party of $74,184 and an increase in~~ accrued interest payable to related party of $~~856~~117.

For the ~~nine~~three months ended ~~September~~March 3031, ~~2020~~2021, net cash used in operating activities was $834,~~842~~822, related to our net loss of $078,264, ~~increased~~reduced by an increase in expenses paid by related party of $~~875~~74,184, and ~~reduced~~accrued note payable interest of $1,159, and increased by a ~~decrease~~change in accounts payable and accrued liabilities of $931,~~717~~901.

During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021, the Company’s sole director and officer paid $~~74,184~~0 and $~~875~~74,184 ~~respectively,~~ on behalf of the Company for business operation purpose, respectively.

Investing Activities

The Company did not use any funds for investing activities during the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022 and ~~2020~~2021.

Financing Activities

The Company provided $~~115~~39,~~000~~500 and $0150,000 by financing activities during the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, and ~~2020~~2021, respectively. During the ~~nine~~three months ended ~~September~~March 3031, ~~2021~~2022, the Company received aloans ~~loan in the amount of $150,000, a loan~~ from related ~~party~~parties in the aggregate amount of $~~115~~54,~~000~~500 and repaid inthe ~~full all~~ outstanding principal ~~loan~~note - related party of $~~150~~15,000 and accrued interest payable of $~~2,250~~225.

During the three months ended March 31, 2021, the Company received a loan of $150,000.

Table of Contents

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of March 31, 2022, the Company has reoccurring losses from operations, an accumulated deficit of $568,971 and has earned no revenues. The Company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending December 31, 2022.

The ability of the Company to emerge from the early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Critical Accounting Policies and Estimates

The ~~preparation~~discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in ~~conformity~~accordance with the accounting principles generally accepted ~~accounting~~in ~~principles~~the ~~requires~~United ~~management~~States toof ~~select~~America. ~~appropriate~~Preparing ~~accounting~~financial ~~policies~~statements ~~and~~requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, ~~revenues~~ and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

Contractual Obligations

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

6 Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to our management, as appropriate, to allow timely decisions regarding required disclosure.

Our management has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, management has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were not effective.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting identified in connection with the evaluation we conducted on the effectiveness of our internal control over financial reporting as of ~~September~~March 3031, ~~2021~~2022, that occurred during our ~~third~~first fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

76 Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no active or pending legal proceedings against us, nor are we involved as a plaintiff in any proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Other than as previously reported in our Current Reports on Form 8-K, we did not sell any unregistered securities during the three-month period ended ~~September~~March 3031, ~~2021~~2022, or subsequent period through the date hereof.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

87 Table of Contents

ITEM 6. EXHIBITS

The following exhibits are included as part of this report:

Exhibit No.		Description
32.1 / 32.2 *		Rule 1350 Certification of Chief Executive and Financial and Accounting Officer
31.1 / 31.2 *		Certification of Principal Executive Officer and Principal Accounting and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act and Rule 13a-14(A) or 15d-14(A) under the Securities Exchange Act of 1934
101.INS *		XBRL Instance Document
32.1 / 32.2 *		Certification of Principal Executive Officer and Principal Accounting and Financial Officer pursuant to18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.SCH *		XBRL Schema Document
101*		Inline XBRL Document Set for the financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.
101.CAL *		XBRL Calculation Linkbase Document
104*		Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.
101.DEF *		XBRL Definition Linkbase Document
101.LAB *		XBRL Label Linkbase Document
101.PRE *		XBRL Presentation Linkbase Document

_______

*Filed herewith

98 Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MED SPA VACATIONS INC.
Dated: November 12, 2021	By:	/s/ Irwin Schneidmill
Dated: April 29, 2022	By:	/s/ Irwin Schneidmill
	Name:	Irwin Schneidmill
	Title:	President, Treasurer and Secretary(Principal Executive Officer and Principal Financial and Accounting Officer)

109

Filing Compare · MED SPA VACATIONS INC.